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Abstract
Background and Aims: The long-term safety and efficacy of allogeneic bone marrow-derived 
mesenchymal stromal cell [bmMSC] therapy in perianal Crohn’s disease [CD] fistulas is unknown. We 
aimed to provide a 4-year clinical evaluation of allogeneic bmMSC treatment of perianal CD fistulas.
Methods: A double-blind dose-finding study for local bmMSC therapy in 21 patients with refractory 
perianal fistulising Crohn’s disease was performed at the Leiden University Medical Center in 2012–
2014. All patients treated with bmMSCs [1 x 107 bmMSCs cohort 1, n = 5; 3 × 107 bmMSCs cohort 2, n = 5; 
9 × 107 bmMSCs cohort 3, n = 5] were invited for a 4-year evaluation. Clinical events were registered, 
fistula closure was evaluated, and anti-human leukocyte antigen [HLA] antibodies were assessed. 
Patients were also asked to undergo a pelvic magnetic resonance imaging [MRI] and rectoscopy.
Results: Thirteen out of 15 patients [87%] treated with bmMSCs were available for long-term 
follow-up. Two non-MSC related malignancies were observed. No serious adverse events thought 
to be related to bmMSC therapy were found. In cohort 2 [n = 4], all fistulas were closed 4 years after 
bmMSC therapy. In cohort 1 [n = 4] 63%, and in cohort 3 [n = 5] 43%, of the fistulas were closed, 
respectively. In none of the patients anti-HLA antibodies could be detected 24 weeks and 4 years 
after therapy. Pelvic MRI showed significantly smaller fistula tracts after 4 years.
Conclusions: Allogeneic bmMSC therapy for CD-associated perianal fistulas is also in the long-term a 
safe therapy. In bmMSC-treated patients, fistulas with closure at Week 24 were still closed after 4 years.
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1. Introduction
A serious, often persistent, complication of Crohn’s disease [CD], 
occurring in 25% of patients, is the development of perianal fis-
tulas.1,2 Perianal fistulas are ulcer tracts that connect the intestinal 
lumen, from the anal canal or rectum, with the perianal skin and are 
associated with a strongly impaired quality of life. Although healing 
of luminal ulcers can be achieved, complete fistula healing in CD is 
difficult and is accompanied by multiple relapses. The combination 
of both biologic therapies and fistula drainage with a non-cutting 
seton is still the cornerstone of treatment. After adequate drainage, 
closure of the tract can be performed using the advancement flap or 
the ligation procedure of the intersphincteric tract. Faecal diversion is 
considered one of the last treatment options, with a first response rate 
of 64%.3 Of the biologic therapies, only infliximab and adalimumab 
have been found effective in randomised controlled trials for the 
closure of perianal fistulas in CD till now.4–6 In the end, only 37% 
of the patients with complex perianal fistulas showed fistula closure 
after a median follow-up of 10 years using combined medico-surgical 
therapies.7 These disappointing healing rates show the need for new 
therapies for perianal fistulising CD.
A promising therapy for perianal CD fistulas is the local injection of 
bone marrow-derived mesenchymal stromal cells [bmMSCs].8 In 2012–
2014, we conducted a randomised placebo-controlled dose-finding study 
for the treatment of perianal CD fistulas with allogeneic bmMSCs.9 That 
study, with a follow-up of 24 weeks, showed that locally administered 
bmMSCs for perianal CD fistulas were safe and feasible. Furthermore, 
the study showed a significant improvement of fistula closure in patients 
treated with 3 x 107 bmMSCs [cohort 2] compared with placebo-treated 
patients, with a reduction in the number of draining fistulas of 86%. 
These promising results have been confirmed in a large multicentre trial 
from Panes et al.10 In that study, fistula closure was reached at Week 
24 in 50% [n = 53] of the 107 patients receiving local adipose tissue-
derived MSCs [Cx601; 12 × 107 MSCs] versus 34% [n = 36] in the 105 
placebo-treated patients. In 2017, Cx601 was approved by the European 
Medicines Agency for the treatment of complex perianal fistulizing CD. 
Here we report on long-term safety and efficacy of local bmMSC therapy 
in CD perianal fistulas.
2. Materials and Methods
2.1. Study design
We asked all patients enrolled in the randomised placebo-controlled 
dose-finding trial ‘Allogeneic bone marrow-derived mesenchymal 
stem cells for the treatment of fistulas in patients with refractory peri-
anal Crohn’s disease’ [NCT01144962; clinicaltrials.gov] for a 4-year 
follow-up evaluation. Full details of the original study design, the pa-
tient eligibility criteria, and the primary outcome of the study after 24 
weeks of follow-up have been published previously9 [Supplementary 
Figure 1, available as Supplementary data at ECCO-JCC online]. In 
short, 21 patients with refractory perianal fistulising CD were en-
rolled. Patients were double-blind randomised in a 5:2 fashion to re-
ceive locally either 0.9% NaCl/5% human albumin solution solution 
with 1 × 107 [cohort 1, n = 5], 3 × 107 [cohort 2, n = 5], or 9 × 107 
[cohort 3, n = 5] bmMSCs or solution with no cells [placebo group, 
n  = 6]. Before local bmMSC or placebo injection, the surgeon per-
formed curettage of the fistula tract[s], the mucosa or skin of, respect-
ively, the internal and external opening, and the internal opening with 
an absorbable polydioxanone II 4/0 suture. Subsequently, half of the 
bmMSCs or placebo suspension was injected via the anus in the fistula 
wall around the closed internal opening. The second half was injected 
in the wall as close as possible to the internal opening by introducing 
the syringe into the fistula tract via the external opening.
Four years after treatment in the clinical trial, patients who re-
ceived bmMSC therapy were asked to visit the outpatient clinic, and 
placebo-treated patients were consulted by phone. Patients treated 
with bmMSCs were asked for clinical events and the clinical fis-
tula closure was evaluated [e.g., no fistula discharge]. Furthermore, 
patients were asked to fill out questionnaires concerning current 
medication use, operation history, the Perianal Disease Activity 
Index [PDAI], adapted Vaizey faecal incontinence score, Crohn’s 
Disease Activity Index [CDAI], Short Form [SF]-36 score, and Short 
Inflammatory Bowel Disease Questionnaire [sIBD-Q]. The CDAI and 
Vaizey score were not calculated in two patients with a stoma. All 
bmMSC-treated patients were also asked to undergo a rectoscopy 
and pelvic magnetic resonance imaging [MRI] 4  years after MSC 
therapy. Pelvic MRI scans before bmMSC therapy and 4 years after 
therapy were evaluated by an experienced radiologist [MNJMW]. 
The diameter of the fistula tract[s] and the presence of collections 
were reported. Improvement on MRI was defined by fistulas con-
taining less fluid compared with the MRI scan made before bmMSC 
therapy. Furthermore, if possible, blood was drawn for standard 
measurements and serum collection.
The original study and the amendment for this follow-up study 
were approved by the Central Committee on Research involving 
Human Subjects and the local Medical Ethical Committee of Leiden 
University Medical Center. All patients gave a renewed written in-
formed consent for the follow-up study. Data were collected between 
May 2016 and May 2018. All authors had access to the study data 
and reviewed and approved the final manuscript.
2.2. Human leukocyte antigen antibody 
measurements
In the serum of patients treated with bmMSCs, donor-specific anti-
bodies against human leukocyte antigen [HLA] class  I  and II were 
measured using the Luminex Screening Assay: Lifecodes Lifescreen 
Deluxe [LMX] kit according to the manufacturer’s manual [Immucor 
Transplant Diagnostics Inc., Stamford, CT, USA]; the modified protocol 
as described by Kamburova et al.11 was used. Provider-suggested def-
initions of the negative and positive discriminations were used. When 
positive, donor specificity was determined by single antigen bead 
assay [Luminex single-antigen [LSA], Lifecodes] according to the 
manufacturer’s protocol. Sera were pre-treated with EDTA before 
testing in LSA. All Luminex tests were analysed with a Luminex 100 
reader. First the serum collected 24 weeks [from two patients only 
Week 12 serum was available] after bmMSC therapy was measured. 
When no antibodies were found after 24 weeks, serum samples 4 years 
after bmMSC therapy were tested when available.
2.3. Statistical analysis
Paired data [before and 4 years after bmMSC therapy] were compared 
using the Paired t-test. Data were analysed using SPSS statistical soft-
ware package [version 23, IBM SPSS Statistics for Windows, IBM Corp, 
Armonk, NY] or GraphPad Prism software [version 7, San Diego, CA] and 
expressed as means ± SEM. p ≤ 0.05 was considered statically significant.
3. Results
3.1. Study population
Two of the 15 bmMSCs-treated patients were not available for 
long-term follow-up [Table 1]. One patient in cohort 1 died due to an 
adenocarcinoma in the caecum, which was already described in the 
original paper of the study,9 and in cohort 2 one patient was lost to 
follow-up. Six patients received placebo, of whom two patients received 
open-label bmMSC therapy in our centre 2 years after the initial study, 
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and one patient was treated with Cx60110 2 years later. These three pa-
tients had draining fistula[s] at the time of these treatments. The other 
three placebo-treated patients were consulted by phone for evaluation 
of fistula drainage. Medication use at the time of the follow-up visit and 
at surgery in the past 4 years are described in Table 2.
3.2. Safety
Clinical events over 4  years after bmMSC therapy were assessed. 
Four patients had developed perianal abscesses, three patients had 
CD activity in the past 4 years, and five patients were treated for 
infections [Table 3]. During the 4-year follow-up visit, we detected 
B-cell lymphoproliferative disease [LPD] in the rectum of a patient 
treated with 3 × 107 bmMSCs [cohort 2] as reported previously.12 
To investigate whether bmMSC therapy contributed to this LPD, we 
analysed the possibility of Epstein-Barr virus [EBV] transfer via the 
MSC product and the persistence of bmMSCs in the LPD tissue, 
using short tandem repeat analysis. Since no EBV-DNA was detected 
in the bmMSC product and no cells containing the DNA of the MSC 
donor were detected in the lymphoproliferative lesion, it was con-
cluded that a relation between this EBV-associated LPD and the 
bmMSC therapy was unlikely, but rather was the result of prolonged 
immunosuppressive therapy.
3.3. Efficacy
The beneficial effect of bmMSC therapy on the number of draining 
fistulas previously reported at Week 24 was maintained after 4 years 
[Figure 1; and Supplementary Table 1, available as Supplementary 
data at ECCO-JCC online]. In cohort 1, 75% [3/4] of the patients 
had complete clinical fistula closure after 4 years, as determined by 
the absence of discharge. In cohort 2, all patients (100% [4/4]) had 
complete clinical fistula closure after 4 years. In contrast, in cohort 
3, only one (20% [1/5]) patient had complete clinical fistula closure; 
however, two patients showed partial fistula closure, with closure 
of either one of their two fistulas (40% [2/5]). In two patients [co-
horts 2 and  3] perianal fistulas closed between Week 24 and the 
4-year follow-up without surgical interventions in the perianal re-
gion. In the three patients in the placebo group, none of the patients 
experienced partial or complete fistula closure at 4 years (0% [0/3]). 
The bmMSCs from one donor [bmMSC-B] showed lower fistula 
healing rates compared with the bmMSCs of the other four MSC 
donors [Supplementary Figure 2, available as Supplementary data at 
ECCO-JCC online].
MRI evaluation after 4 years showed an improvement in the fis-
tula tracts in 67% [6/9] of MSC treated patients [Figure 2A]. In only 
four patients (44% [4/9]) complete fibrotic fistula tracts were seen. 
The maximal fistula diameter found in all treated fistulas before 
bmMSC therapy and 4 years thereafter was measured and showed 
significant improvement [6.1 mm ± 1.2 vs 2.6 mm ± 0.9, p = 0.006] 
[Figure 2B]. In none of the scans the presence of >2-cm collections 
was demonstrated, although in two patients smaller abscesses were 
observed. No de novo fistulas were found.
For each patient, the PDAI, CDAI, Vaizey score and quality of 
life measurements were compared between baseline and 4  years 
later. In nine out of 13 patients, PDAI scores 4 years after bmMSC 
treatment were found to be lower than before bmMSC therapy, 
which however did not reach statistical significance [4.3 vs 3.8, 
p  = 0.585] [Figure 3A]. The CDAI revealed a significantly lower 
disease activity 4  years after bmMSC therapy [46.2 vs 101.5 
p  =  0.014] [Figure 3B]. No difference between the Vaizey score 
at baseline and after 4  years follow-up was found [Figure 3C]. 
Comparison of the SF-36 and sIBDQ before and 4  years after 
bmMSC therapy showed that bmMSC-treated patients had im-
provement of their quality of life [sIBDQ: 54.8 vs 60.1, p = 0.047; 
SF-36 MCS: 42.8 vs 48.1, p  =  0.089; SF-36 PCS: 52.2 vs 52.8, 
p = not significant] [Figure 3D and E].
Table 1. Study population.
Cohort bmMSCs Treated  
patients 
[n]
Patients in  
follow-up 
[n]
Original  
treated  
fistulas 
[n]d
MRI 
[n]
Rectoscopy  
[n]
1 1 × 107 5 4 8 3 3
2 3 × 107 5 4a 6 3 2
3 9 × 107 5 5b 7 3 1
Placebo - 6 3c 3 - -
MRI, magnetic resonance imaging.
aOne patient was consulted by phone due to emigration.
bOne patient was consulted by phone due to long travel time.
cAll with placebo-treated patients were consulted by phone.
dIn patients included in the follow-up.
Table 2. Medication use and surgery. Medication use at the time 
of the 4-year follow-up visit and surgery during past 4  years in 
bmMSC-treated patients.
Cohort 1  
[n = 4]
Cohort 2  
[n = 4]
Cohort 3  
[n = 5]
Age at follow-up, mean, years 
[range]
43 [31–57] 46 [43–51] 38 [26–52]
Male, n [%] 3 [75%] 4 [100%] 1 [20%]
Medication, n [%]    
 No medication 1 [25%] 1 [25%] 2 [40%]
 IFX / ADA 2 [50%] 2 [50%] 2 [40%]
 VED 1 [25%] 1 [25%] -
 Thiopurines/MTX only - - 1 [20%]
Surgery, n [%] in past 4 years    
 I and D 2 [1] - 3 [3] 
 Ileocaecal resection - 1 [1] -
 Rectum extirpation - - 1 [1]
 Setons in situ 1 [25%] - 1 [20%]
IFX, infliximab; ADA, adalimumab; VED, vedolizumab; MTX, metho-
trexate; I and D, incision and drainage.
Table 3. Clinical events in the past 4 years in bmMSC-treated pa-
tients included in the long-term follow-up. Number of adverse 
events in total, [in number of patients].
Cohort 1  
[n = 4]
Cohort 2  
[n = 4]
Cohort 3  
[n = 5]
Perianal abscess 2 [1]  4 [3]
Activity CDa 1 [1] 1 [1] 1 [1]
Infectionb 4 [2] 1 [1] 2 [2]
Gout 1 [1]   
Psoriasis guttae 1 [1]   
Uveitis  2 [1]  
Malignancyc  1 [1]  
CD, Crohn’s disease.
aIncluding diversion proctitis.
bPneumonia, otitis media, fungal infection, periodontal abscess, laryngitis.
cB-cell lymphoproliferative disease.
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3.4. Anti-HLA antibodies
In sera of patients included in the trial, we measured class I and II 
anti-human leukocyte antigen [HLA] antibodies, but none could be 
detected after 24 weeks [n = 15] and 4 years of therapy [n = 9].
4. Discussion
Perianal fistulas remain a common and challenging complication of 
CD, with limited treatment options and invalidating complaints. In 
this follow-up study, we evaluated the long-term safety and efficacy 
of bmMSC therapy as a new therapy for CD-associated perianal 
fistulas; bmMSC therapy was already shown to be a safe and ef-
ficacious option for short-term closure of perianal fistulas in both 
our9 and other clinical trials.10, 13–16 The current study revealed that 
bmMSC therapy is also safe and efficacious in the long-term.
The results after 24 weeks9 showed that in cohorts 1, 2, and 3 re-
spectively, 67%, 86%, and 29% of the perianal fistulas were closed 
versus 33% in the placebo group. In this long-term follow-up, we 
found fistula closure rates of 63%, 100%, and 43% after 4 years 
in the three different MSC cohorts. Therefore we concluded that 
fistula healing persisted. In contrast, in the the placebo-treated pa-
tients, all fistulas were draining [again] after 4 years. Next to clinical 
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Figure 2. bmMSC therapy causes fistula closure confirmed on pelvic MRI. [A] Magnetic resonance images [MRI] of the perianal region of two patients treated 
with bmMSC therapy. Above: images at baseline and after 4 years from a patient treated in cohort 2. The fistula tract is completely closed, with only scar tissue 
being present 4 years after bmMSC therapy. Under: images at baseline and after 4 years from a patient treated in cohort 3. Fistula tracts that contained fluid 
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4 years after MSC therapy [n = 9]; **p <0.01.
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evaluation of fistula closure, we found improvement of the fis-
tula tracts in 67% of the bmMSC-treated patients on pelvic MRI. 
However, complete fibrosis of fistula tracts was only observed in 
44% of the patients. These results are in line with previous reports, 
showing that fistula tracks persisted on MRI despite [long-term] 
clinical remission.17 Most of the patients evaluated in this long-term 
follow-up study experienced fistula closure already before 24 weeks 
of bmMSC treatment, but in two patients the fistula[s] closed only 
after 24 weeks [cohorts 2 and 3]. However, due to the low number 
of patients in our study and the loss of two patients in the long-term 
follow-up, caution is advised interpreting these results.
Besides high fistula closure rates in bmMSC-treated patients, 
we also observed a significantly higher quality of life in bmMSC-
treated patients 4 years after therapy compared with their own 
baseline results. This endpoint is important, since this directly 
reviews the effect of fistula closure on daily life. However, we 
also found a lower CDAI in bmMSC=treated patients, suggesting 
that these patients had an overall lower CD activity 4 years later, 
which could also result in a better quality of life. In the future, it 
would be interesting to take work productivity and life style re-
striction into account when evaluating bmMSC therapy for peri-
anal fistulas.
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Although so far no major safety concerns have been raised in 
previous clinical trials using MSC therapy,18 long-term safety aspects 
should always be evaluated carefully when using cell therapy. In this 
4-year follow-up, one patient developed Epstein-Barr virus [EBV]-
positive B-cell proliferative disease in the rectum 4 years after treat-
ment with EBV-negative MSCs, which is described in a case report.12 
In the end it was concluded that this LPD was not related to bmMSC 
therapy, but more likely was the result of prolonged immunosup-
pressive therapy since this patient used azathioprine, adalimumab, 
and methotrexate in the past, and currently vedolizumab. However, 
the possibility of additional local immunosuppression by bmMSC 
therapy cannot be discarded completely. Furthermore, as already 
earlier described and judged not related to the bmMSCtherapy,9 one 
patient in our study died due to an adenocarcinoma in the caecum 
2  years after treatment. Notwithstanding their complete different 
origin and without any expected relation to MSC therapy, these en-
countered malignancies warrant at least prudent [pre]-selection of 
patients and continuous long-term monitoring of local MSC therapy.
To date, only a few papers evaluated the long-term outcome of 
patients treated locally with MSCs for refractory CD fistulas in terms 
of safety and efficacy. Ciccocioppo et al.19 showed that autologous 
bmMSCs were a safe therapy in eight patients after 72 months of 
follow-up. The probability of fistula relapse-free survival was 88% 
after 1 year, 50% after 2 years, and 37% after 4 years in this group 
of patients. Since it is still under debate whether autologous MSCs of 
IBD patients could be impaired like MSCs from systemic lupus ery-
thematosus patients,20 these disappointing long-term efficacy data 
could be related to the autologous origin of these cells. Other studies 
concerning local MSC therapy for perianal fistulas only evaluated 
results up to 2 years.21–23 In this regard, Panes et al.22 showed local 
Cx601, MSCs derived from adipose tissue, after 12  months to 
achieve a significantly higher proportion of fistula closure compared 
with controls [56% vs 39%].
Interestingly, in our study none of the patients treated with 
bmMSC therapy developed anti-HLA antibodies after 24 weeks or 
4 years. This is in contrast to the treatment with Cx601,10 in which 
34% [18 of 53] of the MSC-treated patients found negative at base-
line generated anti-HLA class I antibodies after MSC therapy. The 
difference in the percentage of patients who formed anti-HLA anti-
bodies might be explained by the origin of the MSC product, since 
Cx601 is a product consisting of MSCs derived from adipose tissue. 
The clinical relevance of the presence of anti-HLA antibodies is not 
elucidated yet, although no relation with response rates was ob-
served in the Cx601 trial.
Of course, results of bmMSC therapies from different clinical 
trials can only be properly compared when standardised and val-
idated protocols are being used.24 Our proposed protocol includes 
MRI and rectoscopy to localise and classify the tract[s], and closure 
of the internal orifice and curettage of the tract directly before 
bmMSC administration. Only patients without active luminal CD or 
strictures in the distal colon should be eligible.
In conclusion, we have shown that the efficacy of local bmMSC 
therapy for perianal CD fistulas was maintained for up to 4 years 
after treatment. These long-term data show that bmMSC therapy 
is not only able to heal refractory perianal fistulas in CD patients, 
but also to improve patients’ quality of life. Although we have care-
fully judged the serious adverse events reported in this study and 
concluded that there was no relation with bmMSC treatment, more 
long-term safety data are needed, from both clinical trials and daily 
clinical practice, to fully appreciate all safety aspects concerning 
local bmMSC therapy.
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